// App-Quantinova.ai

: Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Researchers

Presenter

  • Ola Landgren

Principal Investigators

  • Ajai Chari

  • Yael C Cohen

  • Andrew Spencer

  • Peter M. Voorhees

  • Jane Estell

  • Irwindeep Sandhu

  • Matthew Jenner

  • Catherine Williams

  • Niels WCJ van de Donk

  • Meral Beksac

  • Hartmut Goldschmidt

  • Philippe Moreau

  • Steven Kuppens

  • Rajesh Bandekar

  • Tobias Neff

  • Annelore Cortoos

  • Pamela L Clemens

  • Ming Qi

  • Homer Adams

  • Craig C Hofmeister

Medical Centers

  • Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

  • "Seragnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

  • Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY

  • Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

  • Malignant Haematology & Stem Cell Transplantation Service, The Alfred, Prahran, Australia

  • Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC

  • Haematology Department, Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Department of Haematology, Northampton General Hospital, Northampton

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Ankara University Department of Medical Oncology, Ankara, Turkey

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germania

  • University Hospital Hotel-Dieu, Nantes, France

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • The Ohio State University, Atlanta, GA

Locations

  • United States

  • Italy

  • Israel

  • Australia

  • Canada

  • United Kingdom

  • Netherlands

  • Turkey

  • Germany

  • France

  • Belgium

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Smoldering myeloma

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • II

Study Id's

  • NCT02316106

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved